Indacaterol

Indacaterol
Clinical data
Trade namesOnbrez, Arcapta
AHFS/Drugs.comInternational Drug Names
License data
Pregnancy
category
  • AU: B3
Routes of
administration
Inhalation
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only
Pharmacokinetic data
Bioavailability43-45 % (inhaled)
MetabolismUGT1A1, CYP3A4
Elimination half-life40-56 h
Identifiers
  • 5-[2-[(5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.218.577 Edit this at Wikidata
Chemical and physical data
FormulaC24H28N2O3
Molar mass392.499 g·mol−1
3D model (JSmol)
  • O=C4/C=C\c1c(c(O)ccc1[C@@H](O)CNC3Cc2cc(c(cc2C3)CC)CC)N4
  • InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1 checkY
  • Key:QZZUEBNBZAPZLX-QFIPXVFZSA-N checkY
 X markNcheckY (what is this?)  (verify)

Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered through a dry powder inhaler.

Medical uses

A Cochrane review found benefit in lung function in people with COPD at least as good as that seen with twice-daily long-acting beta2-agonists.

Pharmacology

Pharmacodynamics

Indacaterol activities
Receptor KiTooltip Ki (pharmacology) (nM) EC50Tooltip half-maximal effective concentration (nM) EmaxTooltip maximal efficacy (%)a
β1 617 251 16%a
β2 43.7 8.71 73%a
β3 3,310 191 113%a
Footnotes: a = Compared to isoprenaline (isoproterenol). Refs:

Indacaterol is a long-acting selective β2-adrenergic receptor agonist.

History

It was approved by the European Medicines Agency (EMA) under the brand name Onbrez Breezhaler on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the brand name Arcapta Neohaler, on July 1, 2011. In 2016, Novartis licensed its U.S. commercial rights for Arcapta Neohaler to Sunovion Pharmaceuticals.

See also